Gary Charles Robb Sells 6,127 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORTGet Rating) insider Gary Charles Robb sold 6,127 shares of the business’s stock in a transaction dated Thursday, May 19th. The stock was sold at an average price of $19.57, for a total value of $119,905.39. Following the transaction, the insider now directly owns 36,446 shares of the company’s stock, valued at approximately $713,248.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Gary Charles Robb also recently made the following trade(s):

  • On Tuesday, May 17th, Gary Charles Robb sold 28,745 shares of Corcept Therapeutics stock. The shares were sold at an average price of $19.55, for a total value of $561,964.75.
  • On Thursday, March 17th, Gary Charles Robb sold 7,512 shares of Corcept Therapeutics stock. The shares were sold at an average price of $24.68, for a total value of $185,396.16.

Shares of CORT stock traded up $0.78 during trading hours on Thursday, hitting $20.25. The company had a trading volume of 894,347 shares, compared to its average volume of 944,337. Corcept Therapeutics Incorporated has a 12 month low of $15.82 and a 12 month high of $25.68. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 1.96 and a beta of 0.54. The firm’s fifty day moving average is $22.71 and its 200 day moving average is $21.29.

Corcept Therapeutics (NASDAQ:CORTGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.03). Corcept Therapeutics had a net margin of 29.42% and a return on equity of 24.23%. The company had revenue of $93.70 million during the quarter, compared to the consensus estimate of $103.23 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, research analysts expect that Corcept Therapeutics Incorporated will post 0.87 earnings per share for the current fiscal year.

Several equities analysts have commented on the company. Canaccord Genuity Group assumed coverage on Corcept Therapeutics in a report on Wednesday, February 2nd. They issued a “buy” rating and a $30.00 price target for the company. Truist Financial assumed coverage on Corcept Therapeutics in a report on Friday, January 28th. They issued a “buy” rating and a $30.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Corcept Therapeutics in a report on Wednesday, February 16th. Finally, StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 6th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, Corcept Therapeutics currently has an average rating of “Buy” and a consensus price target of $27.25.

Hedge funds have recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $67,000. PNC Financial Services Group Inc. grew its position in Corcept Therapeutics by 16.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 7,036 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 992 shares during the last quarter. Point72 Hong Kong Ltd grew its position in Corcept Therapeutics by 283.1% during the 4th quarter. Point72 Hong Kong Ltd now owns 7,707 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 5,695 shares during the last quarter. Captrust Financial Advisors grew its position in Corcept Therapeutics by 87.8% during the 1st quarter. Captrust Financial Advisors now owns 6,805 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 3,181 shares during the last quarter. Finally, Meritage Portfolio Management bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $208,000. Institutional investors own 80.03% of the company’s stock.

About Corcept Therapeutics (Get Rating)

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

See Also

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.